Career Enhancement Program
职业提升计划
基本信息
- 批准号:10628278
- 负责人:
- 金额:$ 25.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvisory CommitteesAwardBasic ScienceCancer CenterCancer Research ProjectClinicalClinical SciencesCollaborationsEducationElectronic MailEthnic PopulationFacultyFinancial SupportFosteringFundingGoalsIndividualInfrastructureInstitutionK-Series Research Career ProgramsLeadershipMalignant NeoplasmsMalignant neoplasm of prostateMassachusettsMentorsMentorshipMissionMonitorPlayPopulationPopulation SciencesPositioning AttributePostdoctoral FellowProcessProstateRequest for ApplicationsResearchResearch PersonnelResourcesRoleSystemTalentsTrainingUnderrepresented PopulationsWomananticancer researchcareercareer developmentcatalystclinical translationdiversity and inclusionearly-career facultygraduate studentinnovationinstructormeetingsmembernext generationoutreachprofessorprogramsracial populationrecruitsocial mediasuccesssupportive environmenttranslational cancer researchweb site
项目摘要
PROJECT SUMMARY – CAREER ENHANCEMENT PROGRAM (CEP)
The goal of the DF/HCC Prostate SPORE Career Enhancement Program (CEP) is to provide resources,
financial support, and mentorship for faculty who are transitioning or have recently transitioned to
independent positions (Instructor or Assistant Professor). The overarching goal of the SPORE CEP is to
attract and nurture investigators as they develop careers translational prostate cancer research in clinical,
basic, and population science. In turn, the DF/HCC Prostate SPORE program as a whole will greatly benefit
through interactions with fresh and diverse ideas and talent. Applications for at least two annual CEP awards
will be solicited broadly across DF/HCC and Massachusetts and will undergo a fair and transparent review
process overseen by CEP leadership (Drs. Paul Nguyen, Lorelei Mucci, and Adam Feldman). Targeted
outreach will focus on women and underrepresented racial and ethnic groups (UREG), who will be actively
encouraged to apply and will be fully supported once funded, both during the CEP funding and beyond. We
have established an Advisory Committee to address inclusion and diversity through recruitment and
retention of UREG and women within the SPORE. To develop the pipeline, an additional annual pre-CEP
award, supported by institutional funds, will be awarded to a graduate student, post-doc, or clinical fellow
from an underrepresented group. Request for Applications will be announced by e-mail and social media,
posted throughout the DF/HCC institutions via message boards and featured on the DF/HCC Prostate
SPORE and Harvard Catalyst websites, and outreach by CEP leaders. The CEP program will help advance
the research careers of faculty by providing funding for independent projects, infrastructure and resources
through the cores, interactions with established prostate cancer investigators through SPORE meetings and
educational sessions, and by establishing a formalized mentorship program. The CEP program will build
upon a strong prior track record of success in enhancing and supporting career development, and is a
critical piece of the overall DF/HCC Prostate SPORE program in our mission to train and develop the next
generation of leaders in prostate cancer translational research.
项目摘要 – 职业提升计划 (CEP)
DF/HCC 前列腺 SPORE 职业提升计划 (CEP) 的目标是提供资源、
为正在过渡或最近过渡到的教师提供财政支持和指导
SPORE CEP 的总体目标是独立职位(讲师或助理教授)。
吸引和培养研究人员在临床、转化前列腺癌研究中发展职业生涯,
反过来,DF/HCC 前列腺 SPORE 计划作为一个整体将大大受益。
通过与新鲜多样的想法和人才的互动申请至少两个年度 CEP 奖项。
将在 DF/HCC 和马萨诸塞州广泛征集,并将接受公平和透明的审查
该流程由 CEP 领导层(Paul Nguyen 博士、Lorelei Mucci 和 Adam Feldman Targeted)监督。
外展活动将重点关注妇女和代表性不足的种族和族裔群体 (UREG),他们将积极
我们鼓励申请,并且一旦获得资助,无论是在 CEP 资助期间还是之后,我们都将得到全力支持。
成立了一个咨询委员会,通过招聘和解决包容性和多样性问题
为了开发管道,需要额外进行年度预 CEP。
由机构资金支持的奖项将颁发给研究生、博士后或临床研究员
来自代表性不足的群体的申请请求将通过电子邮件和社交媒体公布,
通过留言板在整个 DF/HCC 机构中发布,并在 DF/HCC 前列腺上展示
SPORE 和Harvard Catalyst 网站以及CEP 领导人的推广活动将有助于推进CEP 计划。
通过为独立项目、基础设施和资源提供资金来促进教师的研究生涯
通过核心,通过 SPORE 会议与成熟的前列腺癌研究人员进行互动,
教育会议,并通过建立正式的指导计划来建立 CEP 计划。
之前在增强和支持职业发展方面拥有良好的成功记录,并且是
整个 DF/HCC 前列腺 SPORE 计划的关键部分,是我们培训和开发下一代人的使命
前列腺癌转化研究的一代领导者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Himisha Beltran其他文献
Himisha Beltran的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Himisha Beltran', 18)}}的其他基金
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
“DNMT 和 TET1 重编程作为晚期前列腺癌的靶向耐药机制”
- 批准号:
10681632 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer
前列腺癌中 EZH2 和 PARP 抑制反应和耐药性的分子决定因素
- 批准号:
10628273 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Molecular mechanisms underlying lineage plasticity in prostate cancer
前列腺癌谱系可塑性的分子机制
- 批准号:
10375455 - 财政年份:2020
- 资助金额:
$ 25.82万 - 项目类别:
Molecular mechanisms underlying lineage plasticity in prostate cancer
前列腺癌谱系可塑性的分子机制
- 批准号:
10596605 - 财政年份:2020
- 资助金额:
$ 25.82万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
10227729 - 财政年份:2017
- 资助金额:
$ 25.82万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
9357038 - 财政年份:
- 资助金额:
$ 25.82万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
9763525 - 财政年份:
- 资助金额:
$ 25.82万 - 项目类别:
相似海外基金
Advancing Student Potential for Inclusion with Research Experiences (ASPIRE)
通过研究经验提升学生融入的潜力(ASPIRE)
- 批准号:
10678356 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Characterizing the genetic etiology of delayed puberty with integrative genomic techniques
利用综合基因组技术表征青春期延迟的遗传病因
- 批准号:
10663605 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Mentoring the next generation of trainees in patient-oriented, community engaged research in obesity and health equity
指导下一代学员进行以患者为中心、社区参与的肥胖和健康公平研究
- 批准号:
10662072 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
- 批准号:
10643145 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别:
Early life stress impacts molecular and network properties that bias the recruitment of pro-stress BLA circuits
早期生活压力会影响分子和网络特性,从而影响促压力 BLA 回路的募集
- 批准号:
10820820 - 财政年份:2023
- 资助金额:
$ 25.82万 - 项目类别: